CARM
Carisma Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
−22.22%Margins
Gross margin
98.1%
EBITDA margin
25.9%
EBIT margin
20.6%
Net margin
15.3%
FCF margin
-42.6%
-927.6%
Return on equity
122.7%
Return on assets
—
Return on invested capital
9.10x
Asset turnover
-$22.4M
Cash from operations
$0.07
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2025